Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

about

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

P2860

Q33168449-D9329067-D9C1-420C-82DC-4011BEBE9223 Q49953442-AB3AD966-F941-48E5-BC46-5416440C2A71

P2860

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Item

http://www.wikidata.org/entity/Q42400150

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@en

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@nl

type

Item

label

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@en

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@nl

prefLabel

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@en

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@nl

P1476

Phase IB study of cabozantinib ...... r refractory multiple myeloma.

@en

P2093

Aeri Alexander

http://www.w3.org/2001/XMLSchema#string

Alexander M Lesokhin

http://www.w3.org/2001/XMLSchema#string

Andrew J Yee

http://www.w3.org/2001/XMLSchema#string

David J Chung

http://www.w3.org/2001/XMLSchema#string

Guenther Koehne

http://www.w3.org/2001/XMLSchema#string

Hani Hassoun

http://www.w3.org/2001/XMLSchema#string

Heather Landau

http://www.w3.org/2001/XMLSchema#string

Ioanna Tsakos

http://www.w3.org/2001/XMLSchema#string

Neha Korde

http://www.w3.org/2001/XMLSchema#string

Nikoletta Lendvai

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting MET transcription as a therapeutic strategy in multiple myeloma.

Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.

Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.

Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.

P304

2355-2356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-01-694786

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Ola Landgren

Sergio Giralt

P577

2016-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27020089

http://www.w3.org/2001/XMLSchema#string

P932

5003505

http://www.w3.org/2001/XMLSchema#string

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

about

P2860

P2860

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932